Close
Revogene® Carba C

The Revogene Carba C assay provides healthcare systems with a diagnostic solution to enable early detection and management of Carbapenem-Resistant Enterobacteriaceae (CRE) from isolated colonies of Enterobacteriaceae, Acinetobacter baumannii, or Pseudomonas aeruginosa.

Catalog Number: 133499

Support & Documents

Why Revogene Carba C?

Carbapenem-Resistant Enterobacteriaceae (CRE) infections are hazardous to our patients and alarming for healthcare systems. The CDC has deemed CRE an urgent public health threat that requires immediate and aggressive action. 1

Early identification and isolation of colonized or infected patients is key to limiting the spread of these organisms in healthcare settings and to help in better guidance of treatment.

1. https://www.cdc.gov/drugresistance/biggest_threats.html


  • sample_result_icon
    Efficient workflow - Sample to result in 3 easy steps
  • assay_flexibility_icon
    Flexible platform - Run multiple assays with different sample types on a single run
  • expansion_icon
    Platform for growth - Single analyte and multiplex testing capability
  • tech_icon2
    Total solution - Can be paired with Meridian immunoassays for a scalable testing solution

Early detection is key for CRE infection prevention and control. The CDC recommends “detecting and protecting” through early identification of CRE carriers, followed by prevention of transmission through implementation of infection control precautions.

CDC recommends “detecting and protecting"

Definitive answers, confidence in results

Contact Sales

Definitive answers, confidence in results

Contact Sales

Support & Documents

Our support materials aim to be as comprehensive as our Carba C testing solutions.

Click here to access all of our Revogene Carba C product support materials.

Downloadable PDFs

FAQs

Revogene Carba C – 87150 x 5

1. https://www.cdc.gov/drugresistance/biggest_threats.html

2. https://www.cdc.gov/hai/organisms/cre/index.html

3. https://www.cdc.gov/hai/organisms/cre/cre-clinicianfaq.html

4. Neuner, E. & Gallagher J., 2017. Pharmacodynamic and pharmacokinetic considerations in the treatment of critically ill patients infected with carbapenem-resistant Enterobacteriaceae. Virulence. 8(4):440-452.

Get in touch with us

Contact Us

Welcome to

Please select your country to continue

Continue